CH408933A - Process for the preparation of pyrimidine derivatives - Google Patents
Process for the preparation of pyrimidine derivativesInfo
- Publication number
- CH408933A CH408933A CH631961A CH631961A CH408933A CH 408933 A CH408933 A CH 408933A CH 631961 A CH631961 A CH 631961A CH 631961 A CH631961 A CH 631961A CH 408933 A CH408933 A CH 408933A
- Authority
- CH
- Switzerland
- Prior art keywords
- acids
- acid
- functional derivatives
- aminosalicylic
- esters
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 17
- 150000003230 pyrimidines Chemical class 0.000 title claims description 13
- 238000002360 preparation method Methods 0.000 title claims description 4
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title claims description 4
- 239000002253 acid Substances 0.000 claims description 14
- 150000005415 aminobenzoic acids Chemical class 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 13
- 239000007795 chemical reaction product Substances 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 150000008318 pyrimidones Chemical class 0.000 claims description 5
- 150000008512 pyrimidinediones Chemical class 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 2
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 claims 3
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims 2
- 229960004909 aminosalicylic acid Drugs 0.000 claims 2
- 230000003444 anaesthetic effect Effects 0.000 claims 2
- 239000003589 local anesthetic agent Substances 0.000 claims 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 6
- -1 isopropyl ester Chemical class 0.000 description 6
- 239000012043 crude product Substances 0.000 description 5
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- JYYLQSCZISREGY-UHFFFAOYSA-N 2-amino-4-chlorobenzoic acid Chemical compound NC1=CC(Cl)=CC=C1C(O)=O JYYLQSCZISREGY-UHFFFAOYSA-N 0.000 description 1
- IFXKXCLVKQVVDI-UHFFFAOYSA-N 2-amino-5-chlorobenzoic acid Chemical compound NC1=CC=C(Cl)C=C1C(O)=O IFXKXCLVKQVVDI-UHFFFAOYSA-N 0.000 description 1
- JXPDNDHCMMOJPC-UHFFFAOYSA-N 2-hydroxybutanedinitrile Chemical compound N#CC(O)CC#N JXPDNDHCMMOJPC-UHFFFAOYSA-N 0.000 description 1
- IQGMRVWUTCYCST-UHFFFAOYSA-N 3-Aminosalicylic acid Chemical compound NC1=CC=CC(C(O)=O)=C1O IQGMRVWUTCYCST-UHFFFAOYSA-N 0.000 description 1
- XFDUHJPVQKIXHO-UHFFFAOYSA-N 3-aminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 description 1
- QTXSDPJOPCWEME-UHFFFAOYSA-N 4-amino-2-sulfanylbenzoic acid Chemical compound NC1=CC=C(C(O)=O)C(S)=C1 QTXSDPJOPCWEME-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- GVCFFVPEOLCYNN-UHFFFAOYSA-N 5-amino-2-chlorobenzoic acid Chemical compound NC1=CC=C(Cl)C(C(O)=O)=C1 GVCFFVPEOLCYNN-UHFFFAOYSA-N 0.000 description 1
- KZZWQCKYLNIOBT-UHFFFAOYSA-N 5-amino-2-nitrobenzoic acid Chemical compound NC1=CC=C([N+]([O-])=O)C(C(O)=O)=C1 KZZWQCKYLNIOBT-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Verfahren zur Herstellung von Pyrimidin-Derivaten
Der Zweck des erfindungsgemässen Verfahrens ist die Herstellung von neuen Pyrimidinverbmdungen.
In der Literatur wird das Kondensationsprodukt von Dicy, andilamid mit Acetylaceton beschrieben.
Dabei wird folgendes substituiertes Pyrimidin erhal- ten :
EMI1.1
Es ist bekannt, dass die Cyangruppe in dem eben beschriebenen heterocyclischen Kondensationspro- dukt besonders reaktiv ist. So erhält man z. B. in bekannter Weise aus der Verbindung A und p-Chloranilin in saurem Milieu folgendes substituiertes Pyrimidin :
EMI1.2
Das erfindungsgemässe Verfahren ist dadurch gekennzeichnet, dass gegebenenfalls im Benzolring weiter substituierte Aminobenzoesäuren bzw. deren Säureadditionsprodukte oder funktionelle Derivate von solchen Aminobenzoesäuren bzw. deren SÏureadditionsprodukte derart mit Pyrimidinen, Pyrimidonen oder Pyrimidindionen, welche eine-NHCN Gruppe enthalten, umgesetzt werden, da¯ die po- mÏre oder sekundäre Aminogruppe von solchen Aminobenzoesauren bzw. deren Saureadditionspro- dukten oder von funktionellen Derivaten von solchen AminobenzoesÏuren bzw. deren SÏureadditionsprodukten mit der -NHCN-Gruppe der Pyrimidine, Pyrimidone bzw. der Pyrimidindione reagiert.
Man kann das erfindjungsgemässeVeriahren z. B. so durchführen, dass man die Reaktionen in Wasser oder organischen Lösungsmitteln unter Zusatz von Säuren organischer oder anorganischer Natur bei höheren Temperaturen durchführt, man kann die Reaktionen aber auch ohne Anwendung von Lö sungsmitteln durchführen, z. B. im Schmelzfluss bei höheren Temperaturen unter Zusatz von schwer oder nichtflüchtigen Säuren organischer oder anorga- nischer Natur. Die in saurem Milieu erfindungsgemäss erhältlichen Reaktionsprodukte können anschliessend mit säurebindenden Mitteln in ihre freien Basen über- geführt werden.
Bei der Durchführung des erfindungsgemässen Verfahrens kann man als substituierte Aminobenzoesäure z. B. das bekannte und wirkungsvolle Tuberkulostati- kum PAS zur Reaktion bringen. Ferner können erfindungsgemäss z. B. folgende Verbindungen als Reaktionspar, tner eingesetzt werden :
Ester der 4-Amino-2-oxy-benzoesäure, z. B. der
Athylester, Isopropylester, sec. Butylester, beta-ChlorÏthylester, beta-N-Piperidino äthylester, beta-DiÏthylaminoÏthylester,
Ester von Aminobenzoesäuren, z. B. die Methyl- oder Athylester von Anthranilsäure, 4-Chloranthranilsäure, 5-ChloranthranilsÏure,
6-Chlor-3-amino-benzoesäure,
6-Nitro-3-amino-benzoesäure, die Ester von p-Aminobenzoesäuren, z.
B. der Athylester, Propylester, Isobutylester,
Diäthylaminoäthylester,
Dimethylaminomethylbutykster, ferner 4-Amino-2-oxy-benzoesäure, o-AminobenzoesÏure oder deren Substitutions produkte, m-Aminobenzoesäure oder deren Substitutions produkte, p-Aminobenzoesäure oder deren Substitutions pr, oduk, te, 5-AminosalicylsÏure oder deren Substitutions produkte, 3-Aminosalicylsäu. re oder deren Substitutions produkte, ferner : AminothiosalicylsÏuren, z. B.
4-AminothiosalicylsÏure oder deren Substitutionsprodukte oder deren funktionelle
Derivate,
EMI2.1
EMI3.1
Die im Beispiel durchgeführte Reaktion der Verbindung PAS mit dem Pyrimidin A d rfte wie folgt verlaufe. n :
EMI3.2
Unter Annahme obiger Struktur wÏre das eben beschriebene Reaktionsprodukt als einN-Pyrimidinyl N'-salicylyl-guanidin-hydirochlorid anzusprechen.
Bedingung für die Durchführbarkeit des erfin dungsgemässen Verfahrens ist natürlich, dass die Reaktionspartner sterisch nicht gehindert sind. Man kann das erfindungsgemässe Verfahren auch unter Anwendung von Druck durchführen. Die erfindungsgemäss erhÏltlichen Reaktionsprodukte k¯nnen nachträ. glich auf chemischem Wege verändert werden.
So kann man z. B. die erhaltenen Reaktionsprodukte mit geeigneten chemischen Methoden in substituiez ; te Harnstoffe überführen, das, heisst die in Durchiührung des erfindungsgemässen Verfahrens erhaltene Grup- pierung
EMI3.3
in die Gruppierung-NH-CO-NH-überführen. Derartige Verbindungen mit der Gruppierung -NH-CO-NHkönnen pharmakologischen, gegebenenfalls aber auch klinischen Versuchs-und Verwendungszwecken zugeführt werden.
Beispiele f r Pyrimidine, Pyrimidone und Pyri midindione als Ausgangsprodukte beim erfindungs- gemässen Verfahren sind :
EMI3.4
DRP Nr. 158 591, durch Kondensation von Dicyandiamid mit Malonester erhältlich.
EMI3.5
DRP Nr. 158591, durch Kondensation von Dicyandiamid mit Acetessigester erhÏltlich.
EMI4.1
DRP Nr. 158 591, durch Reaktion von Dicyandiamid mit Cyanessigester erhältlich.
EMI4.2
DRP Nrn. 175 588, 175 589, durch Reaktion von Dicyandiamid mit Malonitril oder dialkylierten Malonitrilen erhÏltlich.
Es sei in diesem engeren Zusammenhang auf die Tatsache hingewiesen, dass ganz bestimmte Reak tionsprodukte von organischen Verbindungen, welche reaktionsfähige NH2-und NH-Gruppen enthalten, mit organischen Verbindungen, unter anderen auch Pyrimidinverbindungen, welche reaktionsfähige Cyangruppen enthalten, in jüngerer Zeit als brauch- bare, wertvolle und potente Heilmittel, zum Beispiel als Malaria-Heilmittel, erkannt wurden.
Es sei ferner auf die Tatsache hingewiesen, dass ganz bestimmte Reaktionsprodukte von organischen Verbindungen, welche reaktionsfähige NH2-und NH-Gruppen ent- halten, mit organischen Verbindungen, welche reak tionsfähige Cyangruppen enthalten, die Fähigkeit besitzen, den Blutzucker-Spiegel von Menschen und Tieren mehr oder weniger stark zu senken.
Die erfindungsgemäss erhältlichen Pyrimidin- Derivate können pharmakologischen, gegebenenfalls auch klinischen Versuchs-und Verwendungszwecken zugeführt werden.
In dem Beispiel bedeuten die Teile, sofern nichts anderes angegeben ist, Gewichtsteile. Die Ge- wichtsteile verhalten sich zu den Volumteilen wie Gramm zu Kubikcentimeter.
Beispiel
Herstellung des Kondensationsproduktes von Dicyandiamid mit Acetylaceton (Abkürzung KP) :
Man löst I Teil Na-Hydroxyd in 500 Volumteilen Wasser, setzt zu dieser Lösung 50 Teile Di cyandiamid und 82, 5 Teile Acetylaceton zu und erwärmt unter Rückfluss. Man hält die Reaktions- lösung etwa 10 Stunden oder länger unter Rückfluss und dampft die Lösung auf ein kleines Volumen (etwa 80 Volumteile) ein. Das Kondensationspro- dukt fällt beim Erkalten der konzentrierten Lösung als Kristallbrei aus. a) 50 Volumteile Wasser werden mit 5 Volum teilen Salzsäure konz. versetzt.
Anschliessend bringt man in diese salzsaure Lösung 5 Teile KP (Rohpro- dukt) und 5, 2 Teile PAS und erwärmt unter Rückfluss.
Dabei gehen die Reaktionspartner nach kurzer Zeit in Lösung, kurz darauf fällt ein weisser kristalliner Niederschlag aus. Man hält etwa 1 Stunde oder länger unter R okflu¯, 1ϯt erkalten und filtriert.
Ausbeute Rohprodukt 2, 1 Teile, sehr schwer l¯slich Alkohol und Eisessig, kristallisiert aus Eisessig.
Smp. Rohprodukt 250-255 C. b) Man bringt das salzsaure Filtrat von a) mit verdünnter Natronlauge auf ein pH von etwa 7-8. Dabei fällt ein weisser Niederschlag aus. Ausbeute Rohprodukt 1, 1 Teile, schlecht löslich Alkohol und Eisessig. Smp. Rohprodukt 11Q-120 C. Es dürfte sich dabei um die freie Base des Reaktions produktes a) handeln.
Process for the preparation of pyrimidine derivatives
The purpose of the process according to the invention is the production of new pyrimidine compounds.
The condensation product of dicy, andilamide with acetylacetone is described in the literature.
The following substituted pyrimidine is obtained:
EMI1.1
It is known that the cyano group in the heterocyclic condensation product just described is particularly reactive. So you get z. B. in a known manner from the compound A and p-chloroaniline in an acidic medium the following substituted pyrimidine:
EMI1.2
The process according to the invention is characterized in that aminobenzoic acids or their acid addition products or functional derivatives of such aminobenzoic acids or their acid addition products which are optionally further substituted in the benzene ring are reacted with pyrimidines, pyrimidones or pyrimidinediones which contain an -NHCN group, so that the po - MÏre or secondary amino groups of such aminobenzoic acids or their acid addition products or of functional derivatives of such aminobenzoic acids or their acid addition products reacts with the -NHCN group of the pyrimidines, pyrimidones or the pyrimidinediones.
One can use the inventive method e.g. B. carry out so that the reactions are carried out in water or organic solvents with the addition of acids of organic or inorganic nature at higher temperatures, but you can also carry out the reactions without the use of solvents, such. B. in the melt flow at higher temperatures with the addition of low or non-volatile acids of organic or inorganic nature. The reaction products obtainable according to the invention in an acidic medium can then be converted into their free bases using acid-binding agents.
When carrying out the process according to the invention, substituted aminobenzoic acid such. For example, the well-known and effective tuberculostati- cal drug PAS reacts. Furthermore, according to the invention, for. B. the following compounds can be used as reaction partners:
Esters of 4-amino-2-oxy-benzoic acid, e.g. B. the
Ethyl ester, isopropyl ester, sec.Butyl ester, beta-chloroethyl ester, beta-N-piperidino ethyl ester, beta-diethylamino ethyl ester,
Esters of aminobenzoic acids, e.g. B. the methyl or ethyl esters of anthranilic acid, 4-chloranthranilic acid, 5-chloranthranilic acid,
6-chloro-3-aminobenzoic acid,
6-nitro-3-aminobenzoic acid, the esters of p-aminobenzoic acids, e.g.
B. the ethyl ester, propyl ester, isobutyl ester,
Diethylaminoethyl ester,
Dimethylaminomethylbutykster, also 4-amino-2-oxy-benzoic acid, o-aminobenzoic acid or its substitution products, m-aminobenzoic acid or its substitution products, p-aminobenzoic acid or its substitution pr, oduk, te, 5-aminosalicylic acid or its substitution, 3 - Amino salicylic acid. re or their substitution products, also: AminothiosalicylsÏuren, z. B.
4-aminothiosalicylic acid or its substitution products or their functional ones
Derivatives,
EMI2.1
EMI3.1
The reaction of the compound PAS with the pyrimidine A d carried out in the example should proceed as follows. n:
EMI3.2
Assuming the above structure, the reaction product just described would be described as an N-pyrimidinyl N'-salicylyl-guanidine hydirochloride.
The condition for the feasibility of the method according to the invention is of course that the reactants are not sterically hindered. The process according to the invention can also be carried out using pressure. The reaction products obtainable according to the invention can subsequently. could be changed chemically.
So you can z. B. the reaction products obtained with suitable chemical methods in substitution; Transferring the ureas, that is, the grouping obtained in carrying out the process according to the invention
EMI3.3
convert into the group-NH-CO-NH-. Such compounds with the grouping -NH-CO-NH can be used for pharmacological purposes and, if appropriate, also for clinical experimental purposes.
Examples of pyrimidines, pyrimidones and pyrimidinediones as starting products in the process according to the invention are:
EMI3.4
DRP No. 158 591, obtainable by condensation of dicyandiamide with malonic ester.
EMI3.5
DRP No. 158591, obtainable by condensation of dicyandiamide with acetoacetic ester.
EMI4.1
DRP No. 158 591, obtainable by reacting dicyandiamide with cyanoacetic ester.
EMI4.2
DRP nos. 175 588, 175 589, obtainable by reacting dicyandiamide with malonitrile or dialkylated malonitriles.
It should be pointed out in this closer context that very specific reaction products of organic compounds which contain reactive NH2 and NH groups with organic compounds, including pyrimidine compounds which contain reactive cyano groups, have recently been considered useful. Bare, valuable, and potent remedies, for example as malaria remedies, have been recognized.
It should also be pointed out that very specific reaction products of organic compounds which contain reactive NH2 and NH groups with organic compounds which contain reactive cyano groups have the ability to reduce the blood sugar level of humans and animals to lower it more or less.
The pyrimidine derivatives obtainable according to the invention can be used for pharmacological and, if appropriate, also clinical test purposes.
In the example, the parts are parts by weight unless otherwise specified. The parts by weight are related to the parts by volume as grams to cubic centimeters.
example
Preparation of the condensation product of dicyandiamide with acetylacetone (abbreviation KP):
I part of sodium hydroxide is dissolved in 500 parts by volume of water, 50 parts of dicyandiamide and 82.5 parts of acetylacetone are added to this solution and the mixture is heated under reflux. The reaction solution is refluxed for about 10 hours or longer and the solution is evaporated to a small volume (about 80 parts by volume). The condensation product precipitates out as a crystal slurry when the concentrated solution cools. a) 50 parts by volume of water are concentrated with 5 parts by volume of hydrochloric acid. offset.
Subsequently, 5 parts of KP (crude product) and 5, 2 parts of PAS are brought into this hydrochloric acid solution and heated under reflux.
The reactants go into solution after a short time, shortly afterwards a white crystalline precipitate separates out. It is kept under R okflū for about 1 hour or longer, 1ϯt cool and filtered.
Yield of crude product 2.1 parts, very poorly soluble alcohol and glacial acetic acid, crystallized from glacial acetic acid.
M.p. crude product 250-255 C. b) The hydrochloric acid filtrate from a) is brought to a pH of about 7-8 with dilute sodium hydroxide solution. A white precipitate separates out. Yield of crude product 1, 1 part, poorly soluble alcohol and glacial acetic acid. M.p. crude product 11Q-120 C. It should be the free base of reaction product a).
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH631961A CH408933A (en) | 1965-05-20 | 1965-05-20 | Process for the preparation of pyrimidine derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH631961A CH408933A (en) | 1965-05-20 | 1965-05-20 | Process for the preparation of pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH408933A true CH408933A (en) | 1966-03-15 |
Family
ID=4307666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH631961A CH408933A (en) | 1965-05-20 | 1965-05-20 | Process for the preparation of pyrimidine derivatives |
Country Status (1)
| Country | Link |
|---|---|
| CH (1) | CH408933A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0121082A1 (en) * | 1983-03-04 | 1984-10-10 | Bayer Ag | Guanidin derivatives |
-
1965
- 1965-05-20 CH CH631961A patent/CH408933A/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0121082A1 (en) * | 1983-03-04 | 1984-10-10 | Bayer Ag | Guanidin derivatives |
| US4602938A (en) * | 1983-03-04 | 1986-07-29 | Bayer Aktiengesellschaft | N'-(substituted-pyrimidin-2-yl)-N"-substituted-N",N"'-bis-(substituted-benzenesulphonyl)-guanidines as herbicides |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0019811A1 (en) | Pyrimidine compounds, process for their preparation, pharmaceutical compositions containing them and their therapeutical use | |
| DE2156720A1 (en) | Pyrimido(4,5-d) pyrimidines - prepd from polychloroalkylimino acid chloride and 4-amino uracils, are starting materials for plant | |
| DE1670537A1 (en) | Process for the preparation of new substituted aminopyrimidines | |
| EP0122580B1 (en) | Pyrimidine derivatives, their preparation and pharmaceutical compositions | |
| DE2237632A1 (en) | METHOD FOR PREPARING 1- (4-METHYL-6-METHOXY-2-PYRIMIDINYL) -3-METHYL-5METHOXYPYRAZOLE | |
| CH408933A (en) | Process for the preparation of pyrimidine derivatives | |
| EP0552758B1 (en) | N-5-protected 2,5-diamino-4,6-dichloropyrimidines and process for their preparation | |
| EP0304004B1 (en) | Process for the production of sodium purines | |
| EP0115325B1 (en) | Process of preparation of 2-substituted-5-nitroso-4,6-diamino-pyrimidines | |
| DE2409195C3 (en) | Process for the preparation of imidazole-43-dicarboxamide | |
| EP0378089B1 (en) | Method for the preparation of 2-amino-4-fluoropyrimidine derivatives | |
| DE2216925A1 (en) | Pyrazine derivatives and processes for their preparation | |
| DE737931C (en) | Process for the preparation of 2,4-diaminochinazoline | |
| DE2530814C3 (en) | Process for the preparation of 2,4-diamino-5- (3,4,5-trimethoxybenzyl) pyrimidine | |
| DE2411274A1 (en) | NEW 2-NITROTHIENO SQUARE CLAMP ON 2.3-SQUARE BRACKET FOR PYRIMIDINONE DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION | |
| DE1695297C3 (en) | 5-Fluoro-1- (2-tetrahydrofuryl) -uracil and its alkali metal salts, processes for their preparation and agents containing them | |
| CH408932A (en) | Process for the preparation of pyrimidine derivatives | |
| CH395108A (en) | Process for the preparation of pyrimidine derivatives | |
| DE2352107A1 (en) | NEW CHEMICAL COMPOUNDS, THEIR PRODUCTION METHODS AND APPLICATIONS OF THESE COMPOUNDS, IN PARTICULAR TO THE SYNTHESIS 2,4-DIAMINO- (3 ', 4', 5'-TRIMETHOXY-) 1-BENZYL-PYRIMIDINE | |
| AT346848B (en) | PROCESS FOR THE PREPARATION OF 2,4-DIAMINO-5- (2-METHYL-4,5-DIMETHOXYBENZYL) -PYRIMIDINE | |
| DE1670233C (en) | Process for the preparation of pyrimidinecarboxylic acids | |
| Johnson et al. | RESEARCHES ON PYRIMIDINES: THIOCYTOSINE-5-CARBOXYLIC ACID.[FIFTY-SECOND PAPER.] | |
| CH630907A5 (en) | Process for preparing derivatives of 1-carbamoyluracil. | |
| DE2060846A1 (en) | Pyrimidine derivatives | |
| DE1670695A1 (en) | Process for the preparation of pyrimidine derivatives |